Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma

Rijul S. Kshirsagar; Jacob G. Eide; Jacob Harris; Arash Abiri; Daniel M. Beswick; Eugene H. Chang; Nicholas Fung; Michelle Hong; Brian J. Johnson; Michael A. Kohanski; Christopher H. Le; Jivianne T. Lee; Seyed A. Nabavizadeh; Isaac P. Obermeyer; Vivek C. Pandrangi; Carlos D. Pinheiro-Neto; Timothy L. Smith; Carl H. Snyderman; Jeffrey D. Suh; Eric W. Wang; Marilene B. Wang; Garret Choby; Mathew Geltzeiler; Jillian Lazor; Tara C. Mitchell; Edward C. Kuan; James N. Palmer; Nithin D. Adappa

doi:10.1177/19458924241308953

Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma

Rijul S. Kshirsagar, Jacob G. Eide, Jacob Harris, Arash Abiri, Daniel M. Beswick, Eugene H. Chang, Nicholas Fung, Michelle Hong, Brian J. Johnson, Michael A. Kohanski, Christopher H. Le, Jivianne T. Lee, Seyed A. Nabavizadeh, Isaac P. Obermeyer, Vivek C. Pandrangi, Carlos D. Pinheiro-Neto, Timothy L. Smith, Carl H. Snyderman, Jeffrey D. Suh, Eric W. WangMarilene B. Wang, Garret Choby, Mathew Geltzeiler, Jillian Lazor, Tara C. Mitchell, Edward C. Kuan, James N. Palmer, Nithin D. Adappa

Otolaryngology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma. Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma. Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded. Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively. Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.

Original language	English (US)
Pages (from-to)	102-108
Number of pages	7
Journal	American Journal of Rhinology and Allergy
Volume	39
Issue number	2
DOIs	https://doi.org/10.1177/19458924241308953
State	Published - Mar 2025

Keywords

cancer
immunotherapy
malignancy
melanoma
nasal
outcomes
sinonasal
sinonasal mucosal melanoma
sinus
treatment

ASJC Scopus subject areas

Immunology and Allergy
Otorhinolaryngology

Access to Document

10.1177/19458924241308953

Cite this

Kshirsagar, R. S., Eide, J. G., Harris, J., Abiri, A., Beswick, D. M., Chang, E. H., Fung, N., Hong, M., Johnson, B. J., Kohanski, M. A., Le, C. H., Lee, J. T., Nabavizadeh, S. A., Obermeyer, I. P., Pandrangi, V. C., Pinheiro-Neto, C. D., Smith, T. L., Snyderman, C. H., Suh, J. D., ... Adappa, N. D. (2025). Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma. American Journal of Rhinology and Allergy, 39(2), 102-108. https://doi.org/10.1177/19458924241308953

Kshirsagar, RS, Eide, JG, Harris, J, Abiri, A, Beswick, DM, Chang, EH, Fung, N, Hong, M, Johnson, BJ, Kohanski, MA, Le, CH, Lee, JT, Nabavizadeh, SA, Obermeyer, IP, Pandrangi, VC, Pinheiro-Neto, CD, Smith, TL, Snyderman, CH, Suh, JD, Wang, EW, Wang, MB, Choby, G, Geltzeiler, M, Lazor, J, Mitchell, TC, Kuan, EC, Palmer, JN & Adappa, ND 2025, 'Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma', American Journal of Rhinology and Allergy, vol. 39, no. 2, pp. 102-108. https://doi.org/10.1177/19458924241308953

@article{01d0b5dc85b24fc3a7c9d066912770d5,

title = "Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma",

abstract = "Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma. Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma. Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded. Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively. Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.",

keywords = "cancer, immunotherapy, malignancy, melanoma, nasal, outcomes, sinonasal, sinonasal mucosal melanoma, sinus, treatment",

author = "Kshirsagar, {Rijul S.} and Eide, {Jacob G.} and Jacob Harris and Arash Abiri and Beswick, {Daniel M.} and Chang, {Eugene H.} and Nicholas Fung and Michelle Hong and Johnson, {Brian J.} and Kohanski, {Michael A.} and Le, {Christopher H.} and Lee, {Jivianne T.} and Nabavizadeh, {Seyed A.} and Obermeyer, {Isaac P.} and Pandrangi, {Vivek C.} and Pinheiro-Neto, {Carlos D.} and Smith, {Timothy L.} and Snyderman, {Carl H.} and Suh, {Jeffrey D.} and Wang, {Eric W.} and Wang, {Marilene B.} and Garret Choby and Mathew Geltzeiler and Jillian Lazor and Mitchell, {Tara C.} and Kuan, {Edward C.} and Palmer, {James N.} and Adappa, {Nithin D.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = mar,

doi = "10.1177/19458924241308953",

language = "English (US)",

volume = "39",

pages = "102--108",

journal = "American Journal of Rhinology and Allergy",

issn = "1945-8924",

publisher = "OceanSide Publications Inc.",

number = "2",

}

TY - JOUR

T1 - Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma

AU - Kshirsagar, Rijul S.

AU - Eide, Jacob G.

AU - Harris, Jacob

AU - Abiri, Arash

AU - Beswick, Daniel M.

AU - Chang, Eugene H.

AU - Fung, Nicholas

AU - Hong, Michelle

AU - Johnson, Brian J.

AU - Kohanski, Michael A.

AU - Le, Christopher H.

AU - Lee, Jivianne T.

AU - Nabavizadeh, Seyed A.

AU - Obermeyer, Isaac P.

AU - Pandrangi, Vivek C.

AU - Pinheiro-Neto, Carlos D.

AU - Smith, Timothy L.

AU - Snyderman, Carl H.

AU - Suh, Jeffrey D.

AU - Wang, Eric W.

AU - Wang, Marilene B.

AU - Choby, Garret

AU - Geltzeiler, Mathew

AU - Lazor, Jillian

AU - Mitchell, Tara C.

AU - Kuan, Edward C.

AU - Palmer, James N.

AU - Adappa, Nithin D.

PY - 2025/3

Y1 - 2025/3

N2 - Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma. Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma. Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded. Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively. Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.

AB - Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma. Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma. Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded. Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively. Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.

KW - cancer

KW - immunotherapy

KW - malignancy

KW - melanoma

KW - nasal

KW - outcomes

KW - sinonasal

KW - sinonasal mucosal melanoma

KW - sinus

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85214509309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85214509309&partnerID=8YFLogxK

U2 - 10.1177/19458924241308953

DO - 10.1177/19458924241308953

M3 - Article

C2 - 39782303

AN - SCOPUS:85214509309

SN - 1945-8924

VL - 39

SP - 102

EP - 108

JO - American Journal of Rhinology and Allergy

JF - American Journal of Rhinology and Allergy

IS - 2

ER -

Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this